Abaxis (Abaxis) ROCE % : 16.42% (As of Mar. 2018)

View and export this data going back to 1992. Start your Free Trial

What is Abaxis ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Abaxis's annualized ROCE % for the quarter that ended in Mar. 2018 was 16.42%.

Abaxis ROCE % Historical Data

The historical data trend for Abaxis's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abaxis ROCE % Chart

Abaxis Annual Data

Trend

Mar09

Mar10

Mar11

Mar12

Mar13

Mar14

Mar15

Mar16

Mar17

Mar18

ROCE %

Get a 7-Day Free Trial

12.69

16.03

19.73

17.30

13.58

Abaxis Quarterly Data
	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18
ROCE %	Get a 7-Day Free Trial															16.62	12.32	13.47	11.84	16.42

Abaxis ROCE % Calculation

Abaxis's annualized ROCE % for the fiscal year that ended in Mar. 2018 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2018 )		(A: Mar. 2017 )		(A: Mar. 2018 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2018 )		(A: Mar. 2017 )		(A: Mar. 2018 )
	=	38.655	/	( ( (305.646 - 33.443)	+	(341.103 - 43.88) )	/ 2 )
	=	38.655	/	( (272.203	+	297.223)	/ 2 )
	=	38.655	/	284.713
	=	13.58 %

Abaxis's ROCE % of for the quarter that ended in Mar. 2018 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2018 )		(Q: Dec. 2017 )		(Q: Mar. 2018 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2018 )		(Q: Dec. 2017 )		(Q: Mar. 2018 )
	=	48.728	/	( ( (338.763 - 42.383)	+	(341.103 - 43.88) )	/ 2 )
	=	48.728	/	( ( 296.38	+	297.223 )	/ 2 )
	=	48.728	/	296.8015
	=	16.42 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2018) EBIT data.

Abaxis (NAS:ABAX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Abaxis ROCE % Related Terms

Thank you for viewing the detailed overview of Abaxis's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Abaxis (Abaxis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Abaxis Inc (NAS:ABAX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.abaxis.com

Abaxis Inc manufactures point-of-care blood analysis instruments and consumables for medical and veterinary care providers. The medical segment sells Piccolo Chemistry Analyzers, which can provide results about a blood sample in 12 minutes, and related reagents to physicians, hospitals, pharmacies, and other healthcare providers. The veterinary segment generates the majority of the firm's total revenue and sells products to animal hospitals, veterinary clinics, and private research laboratories. Products in this segment include the VetScan VS2 chemistry analyzer, animal-specific reagents, and rapid tests for canine and feline diseases. The vast majority of the firm's revenue comes from North America and Europe.

Executives

Richard Bastiani	director	C/O ABAXIS INC, 3240 WHIPPLE RD, UNION CITY CA 94587
Taylor Dean Ross Jr	officer: CFO and VP of Finance	C/O ABAXIS INC, 3240 WHIPPLE ROAD, UNION CITY CA 94587
Clinton Severson	director, officer: CEO & Board Chairman	C/O ABAXIS INC, 3240 WHIPPLE ROAD, UNION CITY CA 94587
Michael D Casey	director	ALLOS THERAPEUTICS, INC., 11080 CIRCLEPOINT ROAD, SUITE 200, WESTMINSTER CO 80020